Vorinostat Completed Phase 1 Trials for Myelodysplastic Syndromes / Acute Promyelocytic Leukemia (APL) / Leukemia Acute Myeloid Leukemia (AML) Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00875745Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)